Applications of panax saponin-Re in neurocyte protection

A nerve cell protection, ginsenoside technology, applied in the field of medicine, can solve the problem that the protective effect has not been reported.

Inactive Publication Date: 2008-09-03
SHENYANG PHARMA UNIVERSITY
View PDF1 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the protective effect of ginsenos

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of panax saponin-Re in neurocyte protection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] This example relates to the protective effect of ginsenoside-Re on cerebral hypoxia, ischemia and cerebral edema in mice.

[0012] 1.1 Determination of survival time of mice with bilateral common carotid artery and vagus nerve ligation

[0013] Take 40 healthy Kunming mice, half male and half male, and divide them into 4 groups according to body weight and sex balance, 10 mice in each group. That is, the blank control group (0.5% CMC-Na), the ginseng Re low, middle and high dose groups (8, 16, 32 mg / kg), canned gastric administration once a day, continuous administration for 7 days, and the last administration was 1 hour Afterwards, anesthetized with 5% chloral hydrate (350 mg / kg), ligated the bilateral common carotid arteries and vagus nerves, and observed the survival time of the mice (respiration less than or equal to 5 times per minute was considered dead).

[0014] The impact of table 1 ginsenoside-Re on the survival time of mice

[0015] Group

Does ...

Embodiment 2

[0029] This example relates to the protective effect of ginsenoside-Re on cerebral ischemia-reperfusion injury in rats.

[0030] 50 healthy male test rats were divided into 5 groups with 10 rats in each group. Namely sham operation group (Sham surgery, SAM), model control group (0.5% CMC-Na10mL / kg, Vehicle, VEH), ginsenoside-Re low, middle and high dose groups (5, 10, 20 mg / kg). The experimental animals in each group were administered orally for 7 consecutive days, fasted at night after administration on the 6th day, and had free access to drinking water. One hour after the last administration, the middle artery-induced focal cerebral ischemia (MCAO) reperfusion model in rats was blocked by the suture method. Compared with the rats in the sham operation group after MCAO reperfusion for 24 hours, the brain function of the rats was obviously disturbed, and there was obvious cerebral infarction. The ginsenoside-Re in the selected dose range was given by intragastric administrat...

Embodiment 3

[0039] This example relates to the protective effect of ginsenoside-Re on neurons in the CA1 region of the hippocampus in rats with cerebral ischemia and reperfusion.

[0040] Experimental method and grouping are the same as in Example 2. Compared with the nerve cells in the sham operation group, the nerve cells in the CA1 area of ​​the rats after MCAO reperfusion for 24 hours were swollen and deformed, the cell membrane structure was incomplete, and there were different degrees of hyperchromatic nuclei, nuclear pyknosis, increased intercellular space, and obvious interstitial edema . In the administration groups with different concentrations, the hyperchromatic nuclei and nuclear pyknosis of nerve cells were alleviated, the morphology of nerve cells was still normal, interstitial edema was relieved, nucleoli were clearly visible, and necrotic neurons in the ischemic central area were reduced. The results of histopathological examination suggest that: Ginsenoside-Re can impro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of ginsenoside-Re in protecting nerve cells, and belongs to the technology field of medicines. According to the invention, the ginsenoside-Re has the effect of protecting cerebral ischemia, cerebral ischemia reperfusion injury, Parkinson disease, Alzheimer disease and PC12 cells; and can be used for preparing new drugs for preventing and treating neurological diseases such as Parkinson disease, Alzheimer disease, cerebral apoplexy and cerebral ischemia. For a mouse model, the dose of ginsenoside-Re is 8-26mg/kg; for a rat model, the dose of ginsenoside-Re is 5-26mg/kg, and for cell experiments, the dose is 10<-5>-10<-8>mol/L.

Description

Technical field: [0001] The invention belongs to the technical field of medicine and relates to the application of ginsenoside-Re in nerve cell protection. It specifically relates to the protective effect of ginsenoside-Re on Parkinson's disease, Alzheimer's disease, cerebral apoplexy, cerebral ischemia and other neurological diseases and the nerve cell damage caused by them, suggesting that ginsenoside-Re can prevent and treat a variety of brain diseases. and neurological diseases. Background technique: [0002] The damage, aging, and death of nerve cells are irreversible. In many current brain and nervous system diseases, nerve cells are severely damaged and lead to accelerated death, such as Parkinson's disease, Alzheimer's disease, and stroke. , Cerebral ischemia, etc. [0003] Parkinson's disease (PD) is a common chronic neurodegenerative disease that mostly occurs in people over 50 years old, and its incidence gradually increases with age. The prevalence of PD in my ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/575A61P9/10A61P25/28A61P25/16
Inventor 曹颖林徐峰徐成周晓棉徐琲琲
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap